Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes

被引:8
作者
Zhou, Ming [1 ]
Tang, Qi [2 ]
Lang, Lixin [1 ]
Xing, Jun [1 ]
Tatsuoka, Kay [1 ]
机构
[1] Bristol Myers Squibb Co, Global Biometr Sci, POB 4000, Princeton, NJ 08543 USA
[2] Sanofi, Translat Informat, Bridgewater, NJ USA
关键词
conditional power; interim monitoring; longitudinal data; predictive probability; SAMPLE-SIZE; MISSING DATA; DESIGN; STATISTICS; SELECTION; SUCCESS; POWER;
D O I
10.1002/sim.7685
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In clinical research and development, interim monitoring is critical for better decision-making and minimizing the risk of exposing patients to possible ineffective therapies. For interim futility or efficacy monitoring, predictive probability methods are widely adopted in practice. Those methods have been well studied for univariate variables. However, for longitudinal studies, predictive probability methods using univariate information from only completers may not be most efficient, and data from on-going subjects can be utilized to improve efficiency. On the other hand, leveraging information from on-going subjects could allow an interim analysis to be potentially conducted once a sufficient number of subjects reach an earlier time point. For longitudinal outcomes, we derive closed-form formulas for predictive probabilities, including Bayesian predictive probability, predictive power, and conditional power and also give closed-form solutions for predictive probability of success in a future trial and the predictive probability of success of the best dose. When predictive probabilities are used for interim monitoring, we study their distributions and discuss their analytical cutoff values or stopping boundaries that have desired operating characteristics. We show that predictive probabilities utilizing all longitudinal information are more efficient for interim monitoring than that using information from completers only. To illustrate their practical application for longitudinal data, we analyze 2 real data examples from clinical trials.
引用
收藏
页码:2187 / 2207
页数:21
相关论文
共 32 条
  • [1] [Anonymous], 2014, STAT ANAL MISSING DA
  • [2] [Anonymous], 1999, GROUP SEQUENTIAL MET
  • [3] [Anonymous], 1982, Sequential Analysis, DOI DOI 10.1080/07474948208836014
  • [4] Bayesian clinical trials
    Berry, DA
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (01) : 27 - 36
  • [5] Berry SM, 2010, CH CRC BIOSTAT SER, P1, DOI 10.1201/EBK1439825488
  • [6] Not Too Big, Not Too Small: A Goldilocks Approach To Sample Size Selection
    Broglio, Kristine R.
    Connor, Jason T.
    Berry, Scott M.
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (03) : 685 - 705
  • [7] MONITORING CLINICAL-TRIALS BASED ON PREDICTIVE PROBABILITY OF SIGNIFICANCE
    CHOI, SC
    PEPPLE, PA
    [J]. BIOMETRICS, 1989, 45 (01) : 317 - 323
  • [8] Sample size and the probability of a successful trial
    Chuang-Stein, Christy
    [J]. PHARMACEUTICAL STATISTICS, 2006, 5 (04) : 305 - 309
  • [9] Bayesian predictive approach to interim monitoring in clinical trials
    Dmitrienko, A
    Wang, MD
    [J]. STATISTICS IN MEDICINE, 2006, 25 (13) : 2178 - 2195
  • [10] FDA, 2010, DRAFT GUID IND AD DE